Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Metastasis: Going places with VHL.

McCarthy N.

Nat Rev Cancer. 2013 Feb;13(2):78. doi: 10.1038/nrc3450. Epub 2012 Dec 21. No abstract available.

PMID:
23258107
2.

Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.

Vanharanta S, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massagué J.

Nat Med. 2013 Jan;19(1):50-6. doi: 10.1038/nm.3029. Epub 2012 Dec 9.

3.

Pancreatic involvement in Japanese patients with von Hippel-Lindau disease: results of a nationwide survey.

Igarashi H, Ito T, Nishimori I, Tamura K, Yamasaki I, Tanaka M, Shuin T.

J Gastroenterol. 2014 Mar;49(3):511-6. doi: 10.1007/s00535-013-0794-1. Epub 2013 Mar 31.

PMID:
23543325
4.

TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.

Shang D, Liu Y, Yang P, Chen Y, Tian Y.

Urology. 2012 Apr;79(4):966.e1-7. doi: 10.1016/j.urology.2011.12.011. Epub 2012 Feb 15.

PMID:
22341602
5.

Expression of VHL and HIF-1α and Their Clinicopathologic Significance in Benign and Malignant Lesions of the Gallbladder.

Yang Z, Yang Z, Xiong L, Huang S, Liu J, Yang L, Miao X.

Appl Immunohistochem Mol Morphol. 2011 Dec;19(6):534-9. doi: 10.1097/PAI.0b013e318212f001.

PMID:
21415706
6.

[Expression of VHL and HIF-1alpha and its clinical significance in the lung cancer tissue].

Peng Z, Shan C, Wang H.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009 Apr;34(4):331-4. Chinese.

7.

Inactivation of von Hippel-Lindau increases ovarian cancer cell aggressiveness through the HIF1α/miR-210/VMP1 signaling pathway.

Liu T, Zhao L, Chen W, Li Z, Hou H, Ding L, Li X.

Int J Mol Med. 2014 May;33(5):1236-42. doi: 10.3892/ijmm.2014.1661. Epub 2014 Feb 18.

PMID:
24549370
8.

[The current clinical status of kidney cancers in patients with the VHL disease in Japan: a nationwide epidemiological survey].

Shuin T, Shinohara N, Yao M, Yamasaki I, Tamura K, Kamada M.

Nihon Hinyokika Gakkai Zasshi. 2012 May;103(3):552-6. Japanese.

PMID:
22876660
9.
10.

The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells.

Zia MK, Rmali KA, Watkins G, Mansel RE, Jiang WG.

Int J Mol Med. 2007 Oct;20(4):605-11.

PMID:
17786294
11.

Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters.

Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T, Moriyama M, Kobayashi K, Sakai N, Kaneko S, Kawakami S, Baba M, Nakaigawa N, Nagashima Y, Nakatani Y, Hosaka M.

Genes Chromosomes Cancer. 2002 May;34(1):58-68.

PMID:
11921283
12.

Loss of VHL expression contributes to epithelial-mesenchymal transition in oral squamous cell carcinoma.

Zhang S, Zhou X, Wang B, Zhang K, Liu S, Yue K, Zhang L, Wang X.

Oral Oncol. 2014 Sep;50(9):809-17. doi: 10.1016/j.oraloncology.2014.06.007. Epub 2014 Jul 2.

PMID:
24998140
13.

[Endolymphatic sac tumor with von Hippel-Lindau disease: report of two cases with testing of von Hippel-Lindau gene].

Su Y, Shen WD, Wang CC, Han WJ, Liu J, Hou ZH, Song ZG, Huang DL, Han DY, Yang SM.

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013 Nov;48(11):913-8. Chinese.

PMID:
24444636
14.

Nervous system involvement in von Hippel-Lindau disease: pathology and mechanisms.

Vortmeyer AO, Falke EA, Gläsker S, Li J, Oldfield EH.

Acta Neuropathol. 2013 Mar;125(3):333-50. doi: 10.1007/s00401-013-1091-z. Epub 2013 Feb 12. Review.

PMID:
23400300
15.

Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients.

Speisky D, Duces A, Bièche I, Rebours V, Hammel P, Sauvanet A, Richard S, Bedossa P, Vidaud M, Murat A, Niccoli P, Scoazec JY, Ruszniewski P, Couvelard A; GTE Group, Groupe d'Etude des Tumeurs Endocrines..

Clin Cancer Res. 2012 May 15;18(10):2838-49. doi: 10.1158/1078-0432.CCR-11-2759. Epub 2012 Mar 29.

16.

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.

Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Mukeria A, Holcatova I, Schmidt LS, Toro JR, Karami S, Hung R, Gerard GF, Linehan WM, Merino M, Zbar B, Boffetta P, Brennan P, Rothman N, Chow WH, Waldman FM, Moore LE.

Clin Cancer Res. 2008 Aug 1;14(15):4726-34. doi: 10.1158/1078-0432.CCR-07-4921.

17.

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.

Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R.

J Urol. 2008 Sep;180(3):860-5; discussion 865-6. doi: 10.1016/j.juro.2008.05.015. Epub 2008 Jul 17.

PMID:
18635227
18.
19.

Molecular cytogenetic characterization of early and late renal cell carcinomas in von Hippel-Lindau disease.

Phillips JL, Ghadimi BM, Wangsa D, Padilla-Nash H, Worrell R, Hewitt S, Walther M, Linehan WM, Klausner RD, Ried T.

Genes Chromosomes Cancer. 2001 May;31(1):1-9.

PMID:
11284029
20.

In Silico Analysis Identification of a Novel Germ-Line VHL Mutation in a Patient of Malignant Pheochromocytoma.

Kawashima ST, Usui T, Tenjin A, Asai S, Tanaka Y, Hoshikawa M, Shimatsu A, Katabami T.

Endocr Pract. 2014 Jun;20(6):e96-101. doi: 10.4158/EP13403.CR.

PMID:
24518179

Supplemental Content

Support Center